Business Context and Reporting Period
This Form 6-K filing by Prana Biotechnology Limited (noted as Altery Therapeutics Ltd in metadata) covers the quarter ended September 30, 2009. The company is an Australian biotechnology entity admitted to the ASX on the basis of commitments. The report was signed on October 28, 2009.
Key Financial Metrics
| Metric | Value (AUD '000) |
|---|---|
| Revenue (Receipts from customers) | 0 |
| Net Operating Cash Flows | (1,161) |
| Net Investing Cash Flows | (6) |
| Net Financing Cash Flows | 5,684 |
| Net Increase in Cash | 4,517 |
| Cash at End of Quarter | 8,811 |
| Debt/Borrowings | 0 |
The filing does not provide a clear value for net profit or loss, gross margins, or operating expenses beyond cash outflows. Cash outflows for the quarter included $518,000 for research and development, $258,000 for staff costs, and $411,000 for other working capital.
Material Changes
The company generated zero revenue from customers during the period. The most significant financial activity was a capital raise, with proceeds from the issue of shares totaling $6,000,000, offset by $316,000 in capital raising costs. This financing activity resulted in a net cash increase of $4,517,000, raising the cash balance from $4,305,000 at the beginning of the quarter to $8,811,000 at the end.
Outlook, Risks, and Unusual Items
The filing contains no management commentary, forward-looking guidance, or specific risk factors beyond the standard disclosure of non-cash transactions. An unusual non-cash item noted was the issuance of 80,000 options to consultants in lieu of services rendered. The company reported no loan facilities or credit standby arrangements available or used.
Investor Verification Checklist
- Verify the specific terms and dilution impact of the $6,000,000 share issuance.
- Confirm the current status of the company's research and development pipeline given the $518,000 cash outflow.
- Review the company's burn rate relative to the new cash balance of $8.8 million to estimate runway.
- Check for any subsequent filings regarding the 80,000 options issued to consultants.